Compare RDIB & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | CNXU |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.5M | 215.9M |
| IPO Year | 1994 | 2025 |
| Metric | RDIB | CNXU |
|---|---|---|
| Price | $19.88 | $7.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 399.0K | 229.9K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $202,988,000.00 | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $6.85 |
| 52 Week High | $17.77 | $13.66 |
| Indicator | RDIB | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 75.08 | 37.80 |
| Support Level | $10.47 | N/A |
| Resistance Level | $17.40 | $10.41 |
| Average True Range (ATR) | 0.84 | 1.02 |
| MACD | 0.80 | -0.14 |
| Stochastic Oscillator | 72.95 | 0.94 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.